589 related articles for article (PubMed ID: 25502895)
41. Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.
Gajjar A; Bowers DC; Karajannis MA; Leary S; Witt H; Gottardo NG
J Clin Oncol; 2015 Sep; 33(27):2986-98. PubMed ID: 26304884
[TBL] [Abstract][Full Text] [Related]
42. Translational oncology toward benefiting cancer patients: the Sun Yat-sen University Cancer Center experience.
Guerin M; Qian C; Zhong Q; Cui Q; Guo Y; Bei J; Shao J; Zhu X; Huang W; Wu J; Liu R; Liu Q; Wang J; Jia W; Zheng X; Zeng Y
Sci China Life Sci; 2016 Oct; 59(10):1057-1062. PubMed ID: 23132500
[No Abstract] [Full Text] [Related]
43. Progress in precision therapy in pediatric oncology.
O'Donohue T; Farouk Sait S; Glade Bender J
Curr Opin Pediatr; 2023 Feb; 35(1):41-47. PubMed ID: 36377257
[TBL] [Abstract][Full Text] [Related]
44. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
Hollebecque A; Massard C; Soria JC
Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
[TBL] [Abstract][Full Text] [Related]
45. Molecular insights into pediatric brain tumors have the potential to transform therapy.
Gajjar A; Pfister SM; Taylor MD; Gilbertson RJ
Clin Cancer Res; 2014 Nov; 20(22):5630-40. PubMed ID: 25398846
[TBL] [Abstract][Full Text] [Related]
46. Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?
Marquet P; Longeray PH; Barlesi F; ; Ameye V; Augé P; Cazeneuve B; Chatelut E; Diaz I; Diviné M; Froguel P; Goni S; Gueyffier F; Hoog-Labouret N; Mourah S; Morin-Surroca M; Perche O; Perin-Dureau F; Pigeon M; Tisseau A; Verstuyft C
Therapie; 2015; 70(1):1-19. PubMed ID: 25679189
[TBL] [Abstract][Full Text] [Related]
47. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
48. [Research impulses for personalized cancer therapies].
Aktuelle Urol; 2013 Sep; 44(5):349. PubMed ID: 24043531
[No Abstract] [Full Text] [Related]
49. Precision medicine in pediatric solid cancers.
Blattner-Johnson M; Jones DTW; Pfaff E
Semin Cancer Biol; 2022 Sep; 84():214-227. PubMed ID: 34116162
[TBL] [Abstract][Full Text] [Related]
50. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
51. Systems medicine: a real approach for future personalized oncology?
Roukos DH
Pharmacogenomics; 2010 Mar; 11(3):283-7. PubMed ID: 20235782
[No Abstract] [Full Text] [Related]
52. The landscape of precision cancer medicine clinical trials in the United States.
Roper N; Stensland KD; Hendricks R; Galsky MD
Cancer Treat Rev; 2015 May; 41(5):385-90. PubMed ID: 25864024
[TBL] [Abstract][Full Text] [Related]
53. Personalized medicine: present and future of breast cancer management.
Sabatier R; Gonçalves A; Bertucci F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
[TBL] [Abstract][Full Text] [Related]
54. SWOG Cooperative Group biorepository resource: access for scientific research studies.
Hoban CJ; Franklin W; Kopecky KJ; Baker LH
Clin Cancer Res; 2011 Aug; 17(16):5239-46. PubMed ID: 21555374
[TBL] [Abstract][Full Text] [Related]
55. Place of proton radiotherapy in future radiotherapy practice.
Zips D; Baumann M
Semin Radiat Oncol; 2013 Apr; 23(2):149-53. PubMed ID: 23473693
[TBL] [Abstract][Full Text] [Related]
56. Precision Medicine in Gastrointestinal Pathology.
Wang DH; Park JY
Arch Pathol Lab Med; 2016 May; 140(5):449-60. PubMed ID: 27128302
[TBL] [Abstract][Full Text] [Related]
57. Next-generation sequencing in precision oncology: challenges and opportunities.
Kruglyak KM; Lin E; Ong FS
Expert Rev Mol Diagn; 2014 Jul; 14(6):635-7. PubMed ID: 24791810
[TBL] [Abstract][Full Text] [Related]
58. Evolving paradigms for new agent development in pediatric oncology.
Flynn A; Fox E
Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
[TBL] [Abstract][Full Text] [Related]
59. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
60. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.
Pincez T; Clément N; Lapouble E; Pierron G; Kamal M; Bieche I; Bernard V; Fréneaux P; Michon J; Orbach D; Aerts I; Pacquement H; Bourdeaut F; Jiménez I; Thébaud E; Oudot C; Vérité C; Taque S; Owens C; Doz F; Le Tourneau C; Delattre O; Schleiermacher G
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
